ACP-211 vs AV-101

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ACP-211

Developed by Acadia Pharmaceuticals

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07284667 (registry estimate)

No aligned efficacy figure on record for this race.

AV-101

Developed by VistaGen Therapeutics

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT02484456 · Phase 2 · completed

Nineteen participants were randomized to receive AV-101 and placebo in a double-blind crossover design. The primary clinical depression endpoint was not statistically significant at the reported time points; for example, the day-0 comparison was 20.22 with AV-101 versus 20.56 with placebo (p=0.68), and the day-13 comparison was 21.52 versus 19.69 (p=0.26).

Reported efficacy

Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 1); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 2); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 3); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 7); Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 13): Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) (missed)

Result source: NCT02484456

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACP-211AV-101
MADRS, change (acute)—Not reported29.7 vs 27.1+2.6 vs placebowk 1.86 · n 19NCT02484456
5 other results
  • 30.4 vs 28.6 wk 1 · n 19 · Phase 2 · secondary NCT02484456
  • 29.9 vs 30.8 wk 0.43 · n 19 · Phase 2 · secondary NCT02484456
  • 29.5 vs 29.8 wk 0.29 · n 19 · Phase 2 · secondary NCT02484456
  • 28.8 vs 28.8 wk 0.14 · n 19 · Phase 2 · secondary NCT02484456
  • 29.3 vs 29.5 wk 0 · n 19 · Phase 2 · secondary NCT02484456
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ACP-211
—Not reported
AV-101
29.7 vs 27.1+2.6 vs placebowk 1.86 · n 19NCT02484456
5 other results
  • 30.4 vs 28.6 wk 1 · n 19 · Phase 2 · secondary NCT02484456
  • 29.9 vs 30.8 wk 0.43 · n 19 · Phase 2 · secondary NCT02484456
  • 29.5 vs 29.8 wk 0.29 · n 19 · Phase 2 · secondary NCT02484456
  • 28.8 vs 28.8 wk 0.14 · n 19 · Phase 2 · secondary NCT02484456
  • 29.3 vs 29.5 wk 0 · n 19 · Phase 2 · secondary NCT02484456

CGI-S, change (acute)

ACP-211
—Not reported
AV-101
—Not reported

MADRS response

ACP-211
—Not reported
AV-101
—Not reported

MADRS remission

ACP-211
—Not reported
AV-101
—Not reported

Relapse (% of patients)

ACP-211
—Not reported
AV-101
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ACP-211: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ACP-211: 0 of 4 rows · AV-101: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAV-101
Dropout rate
—1,080 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
—1,440 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
Discontinued due to AEs
—1,080 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
—1,440 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
Serious AEs
5.3%1,080 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
5.3%1,440 mg for 1 Week
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
Most frequent reported AEs
1,080 mg for 1 Week
headache 26.3% (placebo 15.8%)
insomnia 15.8% (placebo 10.5%)
musculoskeletal pain 15.8% (placebo 15.8%)
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 1 more result
1,440 mg for 1 Week
abdominal discomfort 5.3% (placebo 10.5%)
asthenia 5.3% (placebo 0%)
cold sweat 5.3% (placebo 0%)
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

AV-101

HAM-D 20.22 vs 20.56 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
20.22 vs 20.06 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
20.75 vs 20.41 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
19.51 vs 20.74 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
21.28 vs 20.43 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
21.52 vs 19.69 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
BDI 25.35 vs 25.79 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
24.76 vs 24.75 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.88 vs 26.14 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.64 vs 24.64 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.82 vs 24.22 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
25.86 vs 23.84 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
HAM-A 15.71 vs 16.2 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
17.3 vs 16.67 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
17.83 vs 17.66 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
16.48 vs 17.87 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
18.42 vs 17.25 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
18.33 vs 16.28 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
MADRS 29.28 vs 29.48 placebo score @ 0wk
absolute change · score
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
show 5 more results
28.75 vs 28.79 placebo score @ 0.14wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
29.51 vs 29.84 placebo score @ 0.29wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
29.85 vs 30.81 placebo score @ 0.43wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
30.45 vs 28.64 placebo score @ 1wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2
29.7 vs 27.06 placebo score @ 1.86wk
NCT02484456 · Phase 2 · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · AV-101's landscape